Hemagglutinin (HA) Proteins from H1 and H3 Serotypes of Influenza A Viruses Require Different Antigen Designs for the Induction of Optimal Protective Antibody Responses as Studied by Codon-Optimized HA DNA Vaccines

Wang, Shixia; Taaffe, Jessica; Parker, Christopher S.; Solórzano, Alicia; Cao, Hong; García‐Sastre, Adolfo; Lu, Shan

doi:10.1128/jvi.01065-06

Cited by 84 publications

(94 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Animals in Group 1 received ½ of the normal human dose of a clinically licensed Both of these HA genes were codon optimized which does not change the original amino acid sequences of the HA antigens. The immunogenicity of these two HA-expressing DNA vaccines has been previously reported in both rabbits and mice models [18]. Each rabbit received a total of 36 µg of the bivalent HA DNA vaccine, delivered by a gene gun.…”

Section: Design Of Immunization Studies In Nzw Rabbitsmentioning

confidence: 97%

“…The codon optimized HA DNA vaccines used in this study were H1 and H3 DNA vaccines expressing the full length wild type HA proteins from A/NewCaledonia/20/99 (H1N1) and A/ Panama/2007/99 (H3N2), respectively, as described in a previous study [18]. A/Panama/ 2007/99 (H3N2) is closely related to A/Wyoming/03/2003 (H3N2).…”

Section: Codon Optimized Ha Dna Vaccinesmentioning

confidence: 99%

“…Half of a human dose (0.25 ml) of TIV was administered by intramuscular (IM) injection at each time point as indicated for Groups 1, 3, 5 and 6. The bivalent H1 and H3 HA DNA vaccines were delivered by a Helios gene gun (BioRad) at the shaved abdominal skin, as previously reported [18]. For each immunization, a total of 36 µg of H1 and H3 HA DNA vaccine (18 µg of each HA DNA vaccine) was delivered to animals in Groups 2, 3, 5 and 6 at each immunization as indicated (Fig.…”

Section: Immunization Of New Zealand White (Nzw) Rabbitsmentioning

confidence: 99%

“…ELISA was conducted to measure the HA-specific antibody (IgG) responses in immunized rabbits, as previously described [18]. The 96-well flat-bottom plates were coated with 100 µl of ConA (50 µg/ml) for 1 hour at room temperature, and washed 5 times with PBS containing 0.1% Triton X-100.…”

Section: Elisa (Enzyme-linked Immunosorbent Assay)mentioning

confidence: 99%

“…Both hemagglutination inhibition (HI) and microneutralization antibody (MN) responses were measured, as previously reported [18]. Sera were treated with receptor-destroying enzyme (RDE; Sigma-Aldrich) as described [19].…”

Section: Assays For Protective Antibodiesmentioning

confidence: 99%

See 4 more Smart Citations

Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

Wang¹,

Parker²,

Taaffe³

et al. 2008

Vaccine

Self Cite

View full text Add to dashboard Cite

The trivalent inactivated vaccine (TIV) is used to prevent seasonal influenza virus infection in humans, however, the immunogenicity of this vaccine may be influenced by the priming effect of previous influenza vaccinations or exposure to antigenically-related influenza viruses. The current study examines the immunogenicity of a clinically licensed TIV in rabbits naïve to influenza antigens. Animals were immunized with either the licensed TIV, a bivalent (H1 and H3) HA DNA vaccine or the combination of both. Temporal and peak level serum anti-influenza virus IgG responses were determined by ELISA. Functional antibody responses were measured by hemagglutination inhibition and microneutralization against either A/NewCaledonia//20/99 (H1N1) or A/Panama/2007/99 (H3N2) influenza viruses. Our results demonstrate that the immunogenicity of the TIV is low in seronegative animals. More significantly, the heterologous DNA prime-TIV boost regimen was more immunogenic than the homologous prime-boost using either TIV or DNA vaccines alone. This finding justifies further investigation of HA DNA vaccines as a priming immunogen for the next generation of vaccines against seasonal or pandemic influenza virus infections.

show abstract

Section: Design Of Immunization Studies In Nzw Rabbitsmentioning

confidence: 97%

Section: Codon Optimized Ha Dna Vaccinesmentioning

confidence: 99%

Section: Immunization Of New Zealand White (Nzw) Rabbitsmentioning

confidence: 99%

Section: Elisa (Enzyme-linked Immunosorbent Assay)mentioning

confidence: 99%

Section: Assays For Protective Antibodiesmentioning

confidence: 99%

See 3 more Smart Citations

Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

Wang¹,

Parker²,

Taaffe³

et al. 2008

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

DNA Immunization

Wang

2013

CP Microbiology

Self Cite

View full text Add to dashboard Cite

DNA immunization was discovered in early 1990s, and its use has been expanded from vaccine studies to a broader range of biomedical research areas, such as the generation of high-quality polyclonal and monoclonal antibodies as research reagents. In this unit, three common DNA immunization methods are described: needle injection, electroporation, and gene gun. In addition, several common considerations related to DNA immunization are discussed.

show abstract

Efficacy of seasonal pandemic influenza hemagglutinin DNA vaccines delivered by electroporation against aseasonal H1N1 virus challenge in mice

Tan

Zhang

et al. 2011

Sci. China Life Sci.

View full text Add to dashboard Cite

Prophylactic DNA vaccines against the influenza virus are promising alternatives to conventional vaccines. In this study, we generated two candidate gene-based influenza vaccines encoding either the seasonal or pandemic hemagglutinin antigen (HA) from the strains A/New Caledonia/20/99 (H1N1) (pV1A5) and A/California/04/2009 (H1N1) (pVEH1), respectively. After verifying antigen expression, the immunogenicity of the vaccines delivered intramuscularly with electroporation was tested in a mouse model. Sera of immunized animals were tested in hemagglutination inhibition assays and by ELISA for the presence of HA-specific antibodies. HA-specific T-cells were also measured in IFN-γ ELISpot assays. The protective efficacy of the candidate influenza vaccines was evaluated by measuring mortality rates and body weight after a challenge with 100 LD(50) of mouse-adapted A/New Caledonia/20/99 (H1N1). Mice immunized with either one of the two vaccines showed significantly higher T cell and humoral immune responses (P<0.05) than the pVAX1 control group. Additionally, the pV1A5 vaccine effectively protected the mice against a lethal homologous mouse-adapted virus challenge with a survival rate of 100% compared with a 40% survival rate in the pVEH1 vaccinated group (P<0.05). Our study indicates that the seasonal influenza DNA vaccine completely protects against the homologous A/New Caledonia/20/99 virus (H1N1), while the pandemic influenza DNA vaccine only partially protects against this virus.

show abstract

Hemagglutinin (HA) Proteins from H1 and H3 Serotypes of Influenza A Viruses Require Different Antigen Designs for the Induction of Optimal Protective Antibody Responses as Studied by Codon-Optimized HA DNA Vaccines

Cited by 84 publications

References 57 publications

Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

DNA Immunization

Efficacy of seasonal pandemic influenza hemagglutinin DNA vaccines delivered by electroporation against aseasonal H1N1 virus challenge in mice

Contact Info

Product

Resources

About